Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma
Open Access
- 4 August 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-17
Abstract
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive subtype of lymphoma usually associated with inferior outcomes. ABC-DLBCL exhibits plasmablastic features and is characterized by aberrancies in the molecular networks controlled by IRF4. The signaling pathways that are dysregulated in ABC-DLBCL are, however, not fully understood. ROCK2 is a serine-threonine kinase whose role in lymphomagenesis is unknown. Here we show that ROCK2 activity is constitutively dysregulated in ABC-DLBCL but not in GCB-DLBCL and BL. We furthermore show that ROCK2 phosphorylates IRF4 and that the ROCK2-mediated phosphorylation of IRF4 modulates its ability to regulate a subset of target genes. In addition to its effects on IRF4, ROCK2 also controls the expression of MYC in ABC-DLBCL by regulating MYC protein levels. ROCK inhibition furthermore selectively decreases the proliferation and survival of ABC-DLBCL in vitro and inhibits ABC-DLBCL growth in xenograft models. Thus, dysregulated ROCK2 activity contributes to the aberrant molecular program of ABC-DLBCL via its dual ability to modulate both IRF4- and MYC-controlled gene networks and ROCK inhibition could represent an attractive therapeutic target for the treatment of ABC-DLBCL.Keywords
Funding Information
- National Institutes of Health (1F31CA196209, 1R01CA194547, R01AR064883)
- Leukemia and Lymphoma Society
- Peter Jay Sharp Foundation
This publication has 48 references indexed in Scilit:
- Rho Kinases in Autoimmune DiseasesAnnual Review of Medicine, 2016
- Germinal centres and B cell lymphomagenesisNature Reviews Immunology, 2015
- Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL‐BFM protocolsGenes, Chromosomes and Cancer, 2014
- Somatic RHOA mutation in angioimmunoblastic T cell lymphomaNature Genetics, 2014
- MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramBlood, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- BATF–JUN is critical for IRF4-mediated transcription in T cellsNature, 2012
- An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signalingMolecular Systems Biology, 2011
- IRF4 addiction in multiple myelomaNature, 2008
- Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling ProjectBlood, 2004